• 1.

    Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

    Article 

    Google Scholar
     

  • 2.

    Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623–40.

    CAS 
    Article 

    Google Scholar
     

  • 3.

    Henley SJ, Ward EM, Scott S, et al. Annual report to the nation on the status of cancer, part I: National cancer statistics. Cancer. 2020;126(10):2225–49.

    Article 

    Google Scholar
     

  • 4.

    Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998–2006.

    Article 

    Google Scholar
     

  • 5.

    da Cunha SG, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Annu Rev Pathol. 2011;6:49–69.

    Article 

    Google Scholar
     

  • 6.

    Wang C, Zhao K, Hu S, et al. Patterns and treatment strategies of osimertinib resistance in T790M-positive non-small cell lung cancer: a pooled analysis. Front Oncol. 2021;11:600844.

    Article 

    Google Scholar
     

  • 7.

    Shang Z, Niu X, Zhang K, et al. FGA isoform as an indicator of targeted therapy for EGFR mutated lung adenocarcinoma. J Mol Med (Berl). 2019;97(12):1657–68.

    CAS 
    Article 

    Google Scholar
     

  • 8.

    Wu SG, Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018;17(1):38.

    Article 

    Google Scholar
     

  • 9.

    Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2(3):e73.

    Article 

    Google Scholar
     

  • 10.

    Christ E, Wild D, Forrer F, et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab. 2009;94(11):4398–405.

    CAS 
    Article 

    Google Scholar
     

  • 11.

    Portha B, Tourrel-Cuzin C, Movassat J. Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass. Exp Diabetes Res. 2011;2011:376509.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 12.

    Hornby PJ, Moore BA. The therapeutic potential of targeting the glucagon-like peptide-2 receptor in gastrointestinal disease. Expert Opin Ther Targets. 2011;15(5):637–46.

    CAS 
    Article 

    Google Scholar
     

  • 13.

    Lei Q, Bi J, Chen H, et al. Glucagon-like peptide-2 improves intestinal immune function and diminishes bacterial translocation in a mouse model of parenteral nutrition. Nutr Res. 2018;49:56–66.

    CAS 
    Article 

    Google Scholar
     

  • 14.

    Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002;54(2):161–202.

    CAS 
    Article 

    Google Scholar
     

  • 15.

    Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–13.

    CAS 
    Article 

    Google Scholar
     

  • 16.

    Yamaoka T, Ohba M, Matsunaga Y, et al. Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib. J Vis Exp. 2019;148:e59473.


    Google Scholar
     

  • 17.

    Lee CB, Stinchcombe TE, Rosenman JG, et al. Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: evolving role of dose-escalated conformal (3-dimensional) radiation therapy. Clin Lung Cancer. 2006;8(3):195–202.

    Article 

    Google Scholar
     

  • 18.

    Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–42.

    CAS 
    Article 

    Google Scholar
     

  • 19.

    Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358(11):1160–74.

    CAS 
    Article 

    Google Scholar
     

  • 20.

    Jung SK, Lee MH, Lim DY, et al. Isoliquiritigenin induces apoptosis and inhibits xenograft tumor growth of human lung cancer cells by targeting both wild type and L858R/T790M mutant EGFR. J Biol Chem. 2014;289(52):35839–48.

    CAS 
    Article 

    Google Scholar
     

  • 21.

    Cappuzzo F, Janne PA, Skokan M, et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol. 2009;20(2):298–304.

    CAS 
    Article 

    Google Scholar
     

  • 22.

    Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26.

    Article 

    Google Scholar
     

  • 23.

    Borst P, Evers R, Kool M, et al. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000;92(16):1295–302.

    CAS 
    Article 

    Google Scholar
     

  • 24.

    Sprowl JA, Ong SS, Gibson AA, et al. A phosphotyrosine switch regulates organic cation transporters. Nat Commun. 2016;7:10880.

    CAS 
    Article 

    Google Scholar
     

  • 25.

    Masur K, Schwartz F, Entschladen F, et al. DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells. Regul Pept. 2006;137(3):147–55.

    CAS 
    Article 

    Google Scholar
     

  • 26.

    Korner M, Rehmann R, Reubi JC. GLP-2 receptors in human disease: high expression in gastrointestinal stromal tumors and Crohn’s disease. Mol Cell Endocrinol. 2012;364(1–2):46–53.

    CAS 
    Article 

    Google Scholar
     

  • 27.

    Koehler JA, Yusta B, Drucker DJ. The HeLa cell glucagon-like peptide-2 receptor is coupled to regulation of apoptosis and ERK1/2 activation through divergent signaling pathways. Mol Endocrinol. 2005;19(2):459–73.

    CAS 
    Article 

    Google Scholar
     

  • 28.

    Zyczynski LE, McHugh JB, Gribbin TE, et al. Alveolar rhabdomyosarcoma in a 69-year-old woman receiving glucagon-like peptide-2 therapy. Case Rep Oncol Med. 2015;2015:107479.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 29.

    Shawe-Taylor M, Kumar JD, Holden W, et al. Glucagon-like petide-2 acts on colon cancer myofibroblasts to stimulate proliferation, migration and invasion of both myofibroblasts and cancer cells via the IGF pathway. Peptides. 2017;91:49–57.

    CAS 
    Article 

    Google Scholar
     

  • 30.

    Iakoubov R, Lauffer LM, Trivedi S, et al. Carcinogenic effects of exogenous and endogenous glucagon-like peptide-2 in azoxymethane-treated mice. Endocrinology. 2009;150(9):4033–43.

    CAS 
    Article 

    Google Scholar
     

  • 31.

    Trivedi S, Wiber SC, El-Zimaity HM, et al. Glucagon-like peptide-2 increases dysplasia in rodent models of colon cancer. Am J Physiol Gastrointest Liver Physiol. 2012;302(8):G840–9.

    CAS 
    Article 

    Google Scholar
     

  • Rights and permissions

    Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

    Disclaimer:

    This article is autogenerated using RSS feeds and has not been created or edited by OA JF.

    Click here for Source link (https://www.biomedcentral.com/)